Today: 9 June 2026
Booking Holdings stock price hits a 52-week low before earnings — what traders watch next
14 February 2026
1 min read

Booking Holdings stock price hits a 52-week low before earnings — what traders watch next

New York, Feb 14, 2026, 11:28 (EST) — The market is closed.

  • Booking Holdings settled at $4,140.60 on Friday, slipping 0.5% for the day. Shares earlier dipped to $4,071.60, marking a new 52-week low.
  • Booking Holdings plans to release its fourth-quarter and full-year 2025 financials on Feb. 18, right after the market closes. The earnings call follows at 4:30 p.m. ET.
  • Online travel stocks moved in opposite directions this day, with Expedia down 6.6% as Airbnb picked up 4.6%.

Booking Holdings (BKNG.O) carved out a new 52-week low Friday, though by the close, shares had pared back most of the drop. Still, the heavyweight online travel name remains under the gun ahead of next week’s earnings.

Why now: Booking’s update drops after a shaky run for online travel stocks. Investors are still gauging early 2026 demand—and just how much the big platforms will have to shell out to keep drawing customers.

With U.S. markets shut Monday for Washington’s Birthday, traders will have to wait until Tuesday to make their next moves. That leaves a short week ahead of the report.

Booking shares kicked off Friday at $4,154.00, swinging from a low of $4,071.60 up to $4,192.00. End-of-day volume hit 619,139 shares, per the company’s closing quote.

That reversal didn’t take long. Booking shares slid 3.56% Thursday to $4,159.10, dropping harder than the broader market and ending a two-day rally, according to MarketWatch data.

Looking at peers hasn’t eased concerns. Expedia Group put out results on Thursday, projecting 2026 revenue growth in the 6% to 9% range. “We delivered a strong finish to a great year,” CEO Ariane Gorin said in the statement. ir.expediagroup.com

Airbnb posted its results Thursday: fourth-quarter revenue climbed 12%, while gross booking value advanced 16%. “That momentum is building, and we expect growth to accelerate in 2026,” said co-founder and CEO Brian Chesky. Airbnb Newsroom

Booking’s outlook takes center stage here, with investors watching closely for hints the company might ramp up marketing to protect its turf. Margins can move sharply—online travel agencies depend on paid search and app pushes to pull in bookings, so any tweaks to that spend show up fast.

Booking’s earnings are projected at $47.58 per share, with revenue pegged at $6.11 billion, analysts told Nasdaq.com in a piece published Thursday, citing Zacks data. The article also pointed out that the consensus EPS estimate has dropped in the past 30 days.

But it’s a double-edged setup. Even a strong quarter might not satisfy if Booking offers a subdued outlook, highlights weaker spring trends, or calls out rising customer acquisition costs. Currency swings and tougher competition can also cloud year-on-year comparisons.

The key event lands Wednesday. Booking will drop results about 4 p.m. ET on Feb. 18, then jump on its conference call at 4:30 p.m. ET. After the long weekend, trading picks up again Tuesday.

Stock Market Today

  • Wheat Prices Mixed as Winter Wheat Gains on U.S. Crop Progress
    June 9, 2026, 9:22 AM EDT. Wheat markets closed mixed on Monday, with winter wheat futures rising across Chicago and Kansas City exchanges, while Minneapolis spring wheat fell slightly. The U.S. Department of Agriculture's Crop Progress report showed 92% of winter wheat heading, 7% ahead of average, and spring wheat planting at 98%, with improving crop conditions. Export inspections dropped 20.65% from last week but marketing year shipments rose 9.13% compared to last year. Ukraine's wheat crop estimate increased by 1.8 million tonnes to 21.7 million tonnes. Futures finished with Chicago SRW wheat up 1 to 3 ¼ cents and Kansas City HRW wheat up 2 ¼ to 9 cents, contrasting the modest decline in Minneapolis spring wheat.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Eli Lilly stock: LLY closes at $1,040 as $1.5 billion pill stockpile comes into focus
Previous Story

Eli Lilly stock: LLY closes at $1,040 as $1.5 billion pill stockpile comes into focus

DraftKings stock price tumbles after 2026 outlook miss; what DKNG traders watch next
Next Story

DraftKings stock price tumbles after 2026 outlook miss; what DKNG traders watch next

Go toTop